Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
$6.55
+6.5%
$5.89
$4.35
$12.38
$309.15M0.43211,288 shs207,928 shs
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
$1.34
+4.7%
$1.20
$0.77
$2.63
$105.79M1.03313,709 shs126,875 shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$7.30
+11.3%
$6.26
$4.58
$9.78
$328.90M1.85526,298 shs723,676 shs
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$10.36
+5.4%
$10.44
$8.46
$29.65
$255.13M0.33112,095 shs46,136 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
+1.82%-3.91%+4.41%-13.14%-14.58%
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
+3.23%-10.49%+16.36%+20.75%-30.81%
CryoPort, Inc. stock logo
CYRX
CryoPort
+2.98%-5.34%+8.61%+5.13%-32.37%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
+0.72%-4.75%+7.31%-38.25%-56.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
1.6232 of 5 stars
3.61.00.00.00.03.30.0
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
2.4699 of 5 stars
3.72.00.00.03.60.00.6
CryoPort, Inc. stock logo
CYRX
CryoPort
3.6158 of 5 stars
4.43.00.00.01.83.30.6
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
1.4158 of 5 stars
3.40.00.00.01.03.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
3.25
Buy$22.00235.88% Upside
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
3.40
Buy$8.67546.77% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.71
Moderate Buy$11.0050.68% Upside
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
2.71
Moderate Buy$41.25298.17% Upside

Current Analyst Ratings Breakdown

Latest CRDL, AURA, CYRX, and RNAC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
5/28/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$22.00
5/23/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$19.00
5/8/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/8/2025
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$41.00 ➝ $40.00
5/5/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00
4/16/2025
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
4/16/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
4/16/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/10/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
4/9/2025
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$41.00 ➝ $41.00
(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/A$3.04 per shareN/A
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/AN/AN/AN/A$0.22 per shareN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M1.60N/AN/A$7.44 per share0.98
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$38.91M6.91N/AN/A($0.27) per share-38.37
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$86.92M-$1.90N/AN/AN/AN/A-58.63%-49.74%8/14/2025 (Estimated)
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-$26.77M-$0.34N/AN/AN/AN/A-209.63%-141.09%7/14/2025 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M-$2.34N/AN/AN/A-50.15%-11.03%-5.54%8/5/2025 (Estimated)
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-$77.42M-$52.83N/AN/AN/A-510.72%N/A-7.01%8/6/2025 (Estimated)

Latest CRDL, AURA, CYRX, and RNAC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$0.47-$0.55-$0.08-$0.55N/AN/A
5/8/2025Q1 2025
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-$0.61-$0.68-$0.07-$0.68$0.69 million$1.10 million
5/7/2025Q1 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
3/31/2025Q4 2024
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-$0.08-$0.07+$0.01-$0.07N/AN/A
3/24/2025Q4 2024
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$0.43-$0.52-$0.09-$0.52N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/AN/A
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/A
11.06
11.06
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
0.01
3.26
3.26
CryoPort, Inc. stock logo
CYRX
CryoPort
0.51
5.56
5.24
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
N/A
12.34
12.34

Institutional Ownership

CompanyInstitutional Ownership
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
96.75%
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
12.49%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
86.95%

Insider Ownership

CompanyInsider Ownership
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
5.40%
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
5.25%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.10%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
60.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
5050.27 million47.55 millionNot Optionable
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
2082.65 million78.31 millionNot Optionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.14 million45.07 millionOptionable
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
6425.95 million10.30 millionOptionable

Recent News About These Companies

Cartesian Therapeutics management to meet with BTIG

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aura Biosciences stock logo

Aura Biosciences NASDAQ:AURA

$6.55 +0.40 (+6.50%)
Closing price 04:00 PM Eastern
Extended Trading
$6.54 0.00 (-0.08%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Cardiol Therapeutics stock logo

Cardiol Therapeutics NASDAQ:CRDL

$1.34 +0.06 (+4.69%)
Closing price 04:00 PM Eastern
Extended Trading
$1.37 +0.03 (+2.24%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$7.30 +0.74 (+11.28%)
Closing price 04:00 PM Eastern
Extended Trading
$7.36 +0.06 (+0.75%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Cartesian Therapeutics stock logo

Cartesian Therapeutics NASDAQ:RNAC

$10.36 +0.53 (+5.39%)
Closing price 04:00 PM Eastern
Extended Trading
$10.32 -0.04 (-0.34%)
As of 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.